Palatin Technologies Inc
F:PTN

Watchlist Manager
Palatin Technologies Inc Logo
Palatin Technologies Inc
F:PTN
Watchlist
Price: 3.3 EUR Market Closed
Market Cap: 34m EUR

Palatin Technologies Inc
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Palatin Technologies Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Palatin Technologies Inc
F:PTN
Pre-Tax Income
-$27m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
-19%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$1.7B
CAGR 3-Years
-52%
CAGR 5-Years
-27%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$9.9B
CAGR 3-Years
30%
CAGR 5-Years
41%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$8.2B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$4.4B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5.1B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
16%
No Stocks Found

Palatin Technologies Inc
Glance View

Market Cap
34m EUR
Industry
Biotechnology

Palatin Technologies Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to address unmet medical needs in various health conditions, particularly in women's health and sexual dysfunction. The company is primarily known for its lead product candidate, Vyleesi (bremelanotide injection), which was approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This groundbreaking therapy offers a novel approach to a condition that has traditionally been underserved, highlighting Palatin’s commitment to improving quality of life for its patients. With a robust pipeline of other potential treatments, the company is positioning itself to be a significant player in the biotech sector. Investors will find Palatin appealing not only for its unique product offerings but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company has established relationships with key healthcare organizations, enabling it to conduct pivotal clinical trials and expand its product visibility. Additionally, leadership at Palatin utilizes a disciplined, value-investing approach, ensuring that resources are allocated wisely towards projects with solid scientific backing and commercial potential. As the company advances its portfolio, it aims to create long-term shareholder value while addressing critical areas of health, making it a compelling opportunity for those looking to invest in the future of biopharmaceutical innovations.

PTN Intrinsic Value
0.13 EUR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Palatin Technologies Inc's Pre-Tax Income?
Pre-Tax Income
-27m USD

Based on the financial report for Dec 31, 2024, Palatin Technologies Inc's Pre-Tax Income amounts to -27m USD.

What is Palatin Technologies Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-19%

Over the last year, the Pre-Tax Income growth was 15%. The average annual Pre-Tax Income growth rates for Palatin Technologies Inc have been 9% over the past three years , and -19% over the past ten years .

Back to Top